Company intelligence / Profile preview

Syntimmune

Boston, Massachusetts, United Statesmedia.alexion.com ↗

Ownership: Private
Employees: ~9
Development stage: Phase 2

Overview

Syntimmune was developing SYNT001, a monoclonal antibody that blocks FcRn-IgG interactions, which was being studied in multiple Phase 1b/2a trials for treating IgG-mediated autoimmune diseases.

Therapeutic areas: Immunology
Modalities: Monoclonal antibodies (specifically humanised IgG4 mAb)
Industry: Biotech

Drug pipeline

3 assets

orilanolimab

Phase 2

Indications: Autoimmune hemolytic anemia

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Syntimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntimmune.

Explore the full profile